 Zacks Investment Research lowered shares of 89bio NASDAQ:ETNB from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The companys lead ... 